Co-Authors
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and ZEEV ESTROV.
Connection Strength
11.405
-
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.
Score: 0.195
-
Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.
Score: 0.178
-
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.
Score: 0.173
-
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood. 1999 Aug 15; 94(4):1486-8.
Score: 0.172
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
Score: 0.172
-
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
Score: 0.162
-
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
Score: 0.161
-
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
Score: 0.160
-
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.
Score: 0.157
-
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191.
Score: 0.156
-
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281.
Score: 0.155
-
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
Score: 0.155
-
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928.
Score: 0.149
-
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
Score: 0.149
-
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6.
Score: 0.145
-
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.
Score: 0.144
-
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 2017 01; 102(1):79-84.
Score: 0.141
-
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435.
Score: 0.141
-
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479.
Score: 0.140
-
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016 08 22; 213(9):1723-40.
Score: 0.139
-
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491.
Score: 0.139
-
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
Score: 0.132
-
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.
Score: 0.131
-
Meir Wetzler, MD. Cancer. 2015 Jul 01; 121(13):2106-7.
Score: 0.127
-
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7.
Score: 0.124
-
Interleukin-7 receptor-a gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med. 2014 Jun; 3(3):550-4.
Score: 0.118
-
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5.
Score: 0.117
-
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.
Score: 0.113
-
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
Score: 0.112
-
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200.
Score: 0.104
-
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7.
Score: 0.103
-
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8.
Score: 0.098
-
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. 2011 Oct; 29(5):1094-7.
Score: 0.091
-
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.
Score: 0.090
-
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62.
Score: 0.089
-
Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia. Blood. 1999 Nov 15; 94(10):3609-11.
Score: 0.088
-
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24.
Score: 0.087
-
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res. 2009 May 01; 69(9):3910-7.
Score: 0.084
-
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.
Score: 0.082
-
Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6.
Score: 0.081
-
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45.
Score: 0.079
-
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007 Dec 01; 67(23):11291-9.
Score: 0.076
-
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55.
Score: 0.072
-
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.
Score: 0.070
-
Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res. 2007 Jan; 31(1):91-5.
Score: 0.069
-
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51.
Score: 0.067
-
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7.
Score: 0.062
-
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664.
Score: 0.061
-
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. 2023; 146(6):523-530.
Score: 0.057
-
The role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835.
Score: 0.056
-
Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003 Aug 01; 102(3):987-95.
Score: 0.055
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood. 2003 Jul 15; 102(2):630-7.
Score: 0.055
-
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res. 2003 Mar; 27(3):259-66.
Score: 0.055
-
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9.
Score: 0.053
-
Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol. 2002 Jun; 117(4):869-74.
Score: 0.052
-
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022 08; 97(8):1005-1012.
Score: 0.052
-
Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665.
Score: 0.051
-
Cellular signalling pathways: new targets in leukaemia therapy. Br J Haematol. 2002 Jan; 116(1):57-77.
Score: 0.051
-
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
Score: 0.049
-
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
Score: 0.049
-
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
Score: 0.049
-
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763.
Score: 0.049
-
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
Score: 0.048
-
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499.
Score: 0.048
-
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.
Score: 0.047
-
Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6.
Score: 0.047
-
Clinical significance of minimal residual disease in leukemia. Int J Oncol. 2000 Dec; 17(6):1277-87.
Score: 0.047
-
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.
Score: 0.047
-
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
Score: 0.046
-
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
Score: 0.046
-
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.
Score: 0.046
-
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331.
Score: 0.046
-
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
Score: 0.046
-
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677.
Score: 0.045
-
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
Score: 0.045
-
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513.
Score: 0.045
-
Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.
Score: 0.044
-
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000 Jan; 36(3-4):263-73.
Score: 0.044
-
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec; 5(12):4041-7.
Score: 0.044
-
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
Score: 0.044
-
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999 Oct 15; 94(8):2844-53.
Score: 0.044
-
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565.
Score: 0.043
-
Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999 Aug 03; 131(3):207-19.
Score: 0.043
-
The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15; 341(3):164-72.
Score: 0.043
-
Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
Score: 0.042
-
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539.
Score: 0.042
-
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 1999 May 01; 93(9):2755-9.
Score: 0.042
-
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861.
Score: 0.042
-
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.
Score: 0.041
-
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.
Score: 0.041
-
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019.
Score: 0.041
-
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.
Score: 0.041
-
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79.
Score: 0.041
-
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 01; 92(9):3090-7.
Score: 0.041
-
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201.
Score: 0.041
-
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369.
Score: 0.040
-
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85.
Score: 0.040
-
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
Score: 0.040
-
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141.
Score: 0.040
-
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998 Jul; 4(7):1661-72.
Score: 0.040
-
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998 Jun 01; 91(11):3995-4019.
Score: 0.040
-
MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
Score: 0.039
-
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
Score: 0.039
-
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832.
Score: 0.039
-
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.
Score: 0.038
-
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
Score: 0.038
-
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40.
Score: 0.038
-
Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018 Jan; 97(1):109-121.
Score: 0.038
-
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
Score: 0.038
-
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
Score: 0.037
-
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597.
Score: 0.037
-
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402.
Score: 0.037
-
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323.
Score: 0.037
-
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
Score: 0.037
-
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01; 28(7):1554-1559.
Score: 0.037
-
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.
Score: 0.037
-
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017 Jul; 92(7):674-682.
Score: 0.037
-
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606.
Score: 0.037
-
Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 Jun 13; 1(14):863-866.
Score: 0.037
-
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
Score: 0.037
-
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659.
Score: 0.036
-
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175.
Score: 0.036
-
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.
Score: 0.036
-
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273.
Score: 0.036
-
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
Score: 0.036
-
Hemophagocytic lymphohistiocytosis in adults: An under recognized entity. BBA Clin. 2017 Jun; 7:36-40.
Score: 0.036
-
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.
Score: 0.035
-
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616.
Score: 0.035
-
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2154-2158.
Score: 0.035
-
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.
Score: 0.034
-
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol. 1996 Mar; 166(3):618-30.
Score: 0.034
-
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.
Score: 0.034
-
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2.
Score: 0.033
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
Score: 0.033
-
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016; 57(1):237-9.
Score: 0.033
-
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21.
Score: 0.032
-
Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7.
Score: 0.032
-
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol. 2015 Jun; 90(6):471-7.
Score: 0.032
-
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81.
Score: 0.032
-
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7.
Score: 0.031
-
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015 Jun; 56(6):1643-50.
Score: 0.031
-
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
Score: 0.031
-
Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6.
Score: 0.031
-
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501.
Score: 0.030
-
Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? J Clin Oncol. 2016 Mar 01; 34(7):e57-60.
Score: 0.030
-
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
Score: 0.030
-
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9.
Score: 0.030
-
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.
Score: 0.029
-
Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 01; 82(3):691-703.
Score: 0.028
-
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7.
Score: 0.028
-
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res. 1993 Jul 15; 53(14):3289-93.
Score: 0.028
-
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013 Aug 08; 122(6):893-901.
Score: 0.028
-
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
Score: 0.028
-
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11.
Score: 0.028
-
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666.
Score: 0.028
-
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
Score: 0.028
-
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med. 1993 Mar 01; 177(3):763-74.
Score: 0.028
-
Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9.
Score: 0.027
-
Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia. 1993 Feb; 7(2):214-20.
Score: 0.027
-
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.
Score: 0.027
-
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood. 2012 Sep 27; 120(13):2768-9.
Score: 0.027
-
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
Score: 0.026
-
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31.
Score: 0.026
-
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):341-4.
Score: 0.026
-
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.
Score: 0.026
-
Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012 Sep; 53(9):1839-41.
Score: 0.026
-
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20.
Score: 0.026
-
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9.
Score: 0.025
-
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991 Sep 15; 78(6):1476-84.
Score: 0.025
-
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3.
Score: 0.025
-
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13.
Score: 0.024
-
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40.
Score: 0.024
-
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877.
Score: 0.024
-
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.
Score: 0.023
-
Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res. 2011 Apr; 35(4):526-33.
Score: 0.023
-
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27.
Score: 0.023
-
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. 2011 Dec; 29(6):1206-12.
Score: 0.023
-
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010 Jun 01; 116(11):2673-81.
Score: 0.023
-
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 09; 116(10):1737-46.
Score: 0.023
-
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct; 29(5):818-26.
Score: 0.023
-
Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res. 2010 Oct; 34(10):1320-4.
Score: 0.022
-
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6.
Score: 0.022
-
Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res. 2010 May; 34(5):605-9.
Score: 0.022
-
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009 Nov 12; 114(20):4361-8.
Score: 0.022
-
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-525.
Score: 0.022
-
Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res. 2010 Feb; 34(2):173-6.
Score: 0.022
-
Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct; 23(10):1755-62.
Score: 0.021
-
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009 Jun 01; 15(11):3820-6.
Score: 0.021
-
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009 May; 89(4):489-496.
Score: 0.021
-
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb; 33(2):212-7.
Score: 0.020
-
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73.
Score: 0.020
-
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008 Aug 15; 112(4):981-9.
Score: 0.020
-
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 01; 68(9):3413-20.
Score: 0.020
-
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008 Mar 15; 112(6):1306-12.
Score: 0.020
-
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96.
Score: 0.019
-
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203.
Score: 0.019
-
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2009 Feb; 31(1):97-105.
Score: 0.019
-
Biphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6.
Score: 0.019
-
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8.
Score: 0.019
-
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
Score: 0.017
-
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood. 2006 Aug 01; 108(3):1001-6.
Score: 0.017
-
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005 Sep 15; 104(6):1230-6.
Score: 0.016
-
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004 Nov 01; 64(21):7927-35.
Score: 0.015
-
Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53.
Score: 0.015
-
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 01; 102(5):1866-8.
Score: 0.014
-
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):81-6.
Score: 0.013
-
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002 Jun; 26(6):551-9.
Score: 0.013
-
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec; 21(6A):3777-84.
Score: 0.013
-
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001 Aug; 15(8):1165-70.
Score: 0.012
-
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 01; 91(11):1964-72.
Score: 0.012
-
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr; 7(4):795-9.
Score: 0.012
-
Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia. 2001 Jan; 15(1):57-61.
Score: 0.012
-
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 01; 89(9):1976-82.
Score: 0.012
-
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000 Sep 15; 96(6):2240-5.
Score: 0.012
-
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9.
Score: 0.011
-
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999 Dec 01; 94(11):3717-21.
Score: 0.011
-
The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther. 1999 Sep; 5(3):159-63.
Score: 0.011
-
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66.
Score: 0.011
-
The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999 Jul; 5(7):1855-61.
Score: 0.011
-
Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res. 1999 Jan; 23(1):63-9.
Score: 0.010
-
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998 Apr; 16(4):1526-31.
Score: 0.010
-
Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma. 1994 Dec; 16(1-2):79-88.
Score: 0.008
-
Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994 Nov 01; 84(9):3142-7.
Score: 0.008
-
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994 Oct; 94(4):1383-9.
Score: 0.008
-
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol. 1993 Jan; 21(1):80-5.
Score: 0.007